Hydrocephalus: historical analysis and considerations for treatment

被引:0
作者
Alexandra Hochstetler
Jeffrey Raskin
Bonnie L. Blazer-Yost
机构
[1] Indiana University Purdue University Indianapolis,Department of Biology
[2] Ann and Robert H. Lurie Children’s Hospital,Division of Pediatric Neurosurgery
[3] Northwestern University Feinberg School of Medicine,Department of Neurosurgery
来源
European Journal of Medical Research | / 27卷
关键词
Hydrocephalus; Cerebrospinal fluid; Drug development; Pathophysiology; Preclinical research; Mechanisms;
D O I
暂无
中图分类号
学科分类号
摘要
Hydrocephalus is a serious condition that affects patients of all ages, resulting from a multitude of causes. While the etiologies of hydrocephalus are numerous, many of the acute and chronic symptoms of the condition are shared. These symptoms include disorientation and pain (headaches), cognitive and developmental changes, vision and sleep disturbances, and gait abnormalities. This collective group of symptoms combined with the effectiveness of CSF diversion as a surgical intervention for many types of the condition suggest that the various etiologies may share common cellular and molecular dysfunctions. The incidence rate of pediatric hydrocephalus is approximately 0.1–0.6% of live births, making it as common as Down syndrome in infants. Diagnosis and treatment of various forms of adult hydrocephalus remain understudied and underreported. Surgical interventions to treat hydrocephalus, though lifesaving, have a high incidence of failure. Previously tested pharmacotherapies for the treatment of hydrocephalus have resulted in net zero or negative outcomes for patients potentially due to the lack of understanding of the cellular and molecular mechanisms that contribute to the development of hydrocephalus. Very few well-validated drug targets have been proposed for therapy; most of these have been within the last 5 years. Within the last 50 years, there have been only incremental improvements in surgical treatments for hydrocephalus, and there has been little progress made towards prevention or cure. This demonstrates the need to develop nonsurgical interventions for the treatment of hydrocephalus regardless of etiology. The development of new treatment paradigms relies heavily on investment in researching the common molecular mechanisms that contribute to all of the forms of hydrocephalus, and requires the concerted support of patient advocacy organizations, government- and private-funded research, biotechnology and pharmaceutical companies, the medical device industry, and the vast network of healthcare professionals.
引用
收藏
相关论文
共 796 条
[1]  
Lifshutz JI(2001)History of hydrocephalus and its treatments Neurosurg Focus 11 1-5
[2]  
Johnson WD(1999)The scientific history of hydrocephalus and its treatment Neurosurg Rev 22 67-93
[3]  
Aschoff A(2018)Founder of modern hydrocephalus diagnosis and therapy: Walter Dandy at the Johns Hopkins Hospital J Neurosurg 56 1746-1748
[4]  
Kremer P(2001)The Monro–Kellie hypothesis: applications in CSF volume depletion Neurology 33 67-79
[5]  
Hashemi B(2022)Syndromic hydrocephalus Neurosurg Clin N Am 110 12-15
[6]  
Kunze S(2022)Brain ventricles as windows into brain development and disease Neuron 35 890-897
[7]  
Blitz AM(2021)Multi-omic analysis elucidates the genetic basis of hydrocephalus Cell Rep 81 788-799
[8]  
Ahmed AK(2017)The genetic landscape of familial congenital hydrocephalus Ann Neurol 387 1682-1683
[9]  
Rigamonti D(2016)Hydrocephalus in children Lancet 6 1449-1454
[10]  
Mokri B(2020)Unlocking the genetic complexity of congenital hydrocephalus Nat Med 82 648-656